Gamida Cell Ltd. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q4 FY2018 As of Dec 31, 2018
Cash and cash equivalents
Marketable securities
Short term deposits
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
CURRENT ASSETS:
Cash and cash equivalents
Marketable securities
Short-term restricted deposit
Inventory
Accounts receivable
Prepaid expenses and other current assets
Total current assets
NON-CURRENT ASSETS:
Restricted deposits
Property, plant and equipment, net
Right-of-use assets
Other assets
Trade payables
Employees and payroll accruals
Current maturities of lease liabilities
Accrued expenses and other payables
Total current liabilities
Liabilities presented at fair value
Employee benefit liabilities, net
Lease liability
Liability to Israel Innovation Authority (IIA)
Total non-current liabilities
Operating lease right-of-use assets
Severance pay fund
Other long-term assets
Total non-current assets
Total assets

CURRENT LIABILITIES:
Trade payables
Employees and payroll accruals
Operating lease liabilities
Accrued expenses and other current liabilities
Accrued interest of convertible senior notes
Convertible senior notes, net
Accrued expenses and other current liabilities
Total current liabilities
NON-CURRENT LIABILITIES:
Convertible senior notes, net
Warrants liability
Accrued severance pay
Long-term operating lease liabilities
Other long-term liabilities
Total non-current liabilities
Total liabilities
SHAREHOLDERS’ EQUITY (DEFICIT):
Ordinary shares of NIS 0.01 par value - Authorized: 100,000,000 shares at December 31, 2020 and 2019; Issued and outstanding: 59,000,153 and 33,670,926 shares at December 31, 2020 and 2019, respectively
Ordinary Shares
Preferred Share
Total ordinary shares of NIS 0.01 par value - Authorized: 100,000,000 shares at December 31, 2020 and 2019; Issued and outstanding: 59,000,153 and 33,670,926 shares at December 31, 2020 and 2019, respectively
Share premium
Capital reserve due to actuarial loss
Reserve from financial assets measured at FVTOCI
Accumulated deficit
Shareholders’ equity
Ordinary Shares
Preferred Share
Total shareholders’ equity
Total liabilities and shareholders’ equity
Ordinary shares of NIS 0.01 par value - Authorized: 325,000,000 shares at March 31, 2024 (unaudited) and at December 31, 2023; Issued 154,204,735 and 144,596,195 at March 31, 2024 (unaudited) and December 31, 2023 respectively; Outstanding: 154,050,953 and 144,443,714 shares at March 31, 2024 (unaudited) and December 31, 2023, respectively
Additional paid-in capital
Accumulated deficit
Total shareholders’ deficit
Total liabilities and shareholders’ deficit

Comments